Which has better earnings & valuation, ANTX or SGP?

Anthem is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Spyglass Pharma N/A N/A -$39.87M -$7.00 N/A

Is ANTX or SGP more profitable?

Anthem's return on equity of -53.52% beat Spyglass Pharma's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Spyglass Pharma N/A -62.40% -24.83%

Does the media refer more to ANTX or SGP?

In the previous week, Spyglass Pharma had 5 more articles in the media than Anthem. MarketBeat recorded 6 mentions for Spyglass Pharma and 1 mentions for Anthem. Spyglass Pharma's average media sentiment score of 0.18 beat Anthem's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Spyglass Pharma 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation & earnings, ANTX or ARDX?

Anthem has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Ardelyx $407.32M 2.07 -$61.60M -$0.22 N/A

Is ANTX or ARDX more profitable?

Anthem has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Ardelyx -12.35% -36.00% -10.77%

Does the media favor ANTX or ARDX?

In the previous week, Ardelyx had 21 more articles in the media than Anthem. MarketBeat recorded 22 mentions for Ardelyx and 1 mentions for Anthem. Ardelyx's average media sentiment score of 0.06 beat Anthem's score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ardelyx 1 Very Positive mention(s) 1 Positive mention(s) 17 Neutral mention(s) 1 Negative mention(s) 2 Very Negative mention(s) Neutral

Is ANTX or GYRE more profitable?

Anthem has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Gyre Therapeutics -15.47% -6.57% -5.35%

Does the media favor ANTX or GYRE?

In the previous week, Gyre Therapeutics had 2 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Gyre Therapeutics and 1 mentions for Anthem. Gyre Therapeutics' average media sentiment score of 0.17 beat Anthem's score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Gyre Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better earnings and valuation, ACHV or ANTX?

Anthem is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Achieve Life Sciences N/A N/A -$54.65M -$1.55 N/A Anthem N/A N/A -$35.17M -$1.07 N/A

Is ACHV or ANTX more profitable?

Anthem's return on equity of -53.52% beat Achieve Life Sciences' return on equity. Company Net Margins Return on Equity Return on Assets Achieve Life Sciences N/A -511.12% -82.35% Anthem N/A -53.52% -48.63%

Does the media refer more to ACHV or ANTX?

In the previous week, Achieve Life Sciences had 8 more articles in the media than Anthem. MarketBeat recorded 9 mentions for Achieve Life Sciences and 1 mentions for Anthem. Achieve Life Sciences' average media sentiment score of 0.43 beat Anthem's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Achieve Life Sciences 2 Very Positive mention(s) 2 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher valuation and earnings, ANTX or IVA?

Anthem has higher earnings, but lower revenue than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Anthem N/A N/A -$35.17M -$1.07 N/A Inventiva $5.07M 142.57 -$400.67M N/A N/A

Is ANTX or IVA more profitable?

Inventiva's return on equity of 0.00% beat Anthem's return on equity. Company Net Margins Return on Equity Return on Assets Anthem N/A -53.52% -48.63% Inventiva N/A N/A N/A

Does the media favor ANTX or IVA?

In the previous week, Inventiva had 18 more articles in the media than Anthem. MarketBeat recorded 19 mentions for Inventiva and 1 mentions for Anthem. Inventiva's average media sentiment score of 0.19 beat Anthem's score of 0.00 indicating that Inventiva is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Anthem 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Inventiva 5 Very Positive mention(s) 5 Positive mention(s) 6 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral

Anthem (ANTX) Competitors

$5.32 -0.29 (-5.19%)

As of 11:18 AM Eastern

Compare

ANTX vs. SGP, ARDX, GYRE, ACHV, and IVA

Should you buy Anthem stock or one of its competitors? Anthem's main competitors and comparable companies include Spyglass Pharma (SGP), Ardelyx (ARDX), Gyre Therapeutics (GYRE), Achieve Life Sciences (ACHV), and Inventiva (IVA). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Anthem compare to Spyglass Pharma?

Anthem (NASDAQ:ANTX) and Spyglass Pharma (NASDAQ:SGP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, valuation, dividends, profitability, risk, earnings, analyst recommendations and institutional ownership.

Anthem is trading at a lower price-to-earnings ratio than Spyglass Pharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Spyglass Pharma	N/A	N/A	-$39.87M	-$7.00	N/A

Anthem's return on equity of -53.52% beat Spyglass Pharma's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Spyglass Pharma	N/A	-62.40%	-24.83%

Anthem presently has a consensus price target of $9.00, suggesting a potential upside of 60.43%. Spyglass Pharma has a consensus price target of $44.00, suggesting a potential upside of 71.94%. Given Spyglass Pharma's stronger consensus rating and higher possible upside, analysts plainly believe Spyglass Pharma is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Spyglass Pharma	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.67

In the previous week, Spyglass Pharma had 5 more articles in the media than Anthem. MarketBeat recorded 6 mentions for Spyglass Pharma and 1 mentions for Anthem. Spyglass Pharma's average media sentiment score of 0.18 beat Anthem's score of 0.00 indicating that Spyglass Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Spyglass Pharma	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.5% of Anthem shares are owned by institutional investors. 22.6% of Anthem shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Spyglass Pharma beats Anthem on 7 of the 12 factors compared between the two stocks.

How does Anthem compare to Ardelyx?

Anthem (NASDAQ:ANTX) and Ardelyx (NASDAQ:ARDX) are both small-cap healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, valuation, profitability, media sentiment, analyst recommendations, earnings, institutional ownership and dividends.

Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market. Comparatively, Ardelyx has a beta of 0.68, meaning that its stock price is 32% less volatile than the broader market.

Anthem currently has a consensus target price of $9.00, suggesting a potential upside of 60.43%. Ardelyx has a consensus target price of $13.90, suggesting a potential upside of 310.03%. Given Ardelyx's stronger consensus rating and higher possible upside, analysts clearly believe Ardelyx is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Ardelyx	2 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.75

Anthem has a net margin of 0.00% compared to Ardelyx's net margin of -12.35%. Ardelyx's return on equity of -36.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Ardelyx	-12.35%	-36.00%	-10.77%

90.5% of Anthem shares are owned by institutional investors. Comparatively, 58.9% of Ardelyx shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Comparatively, 5.3% of Ardelyx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

In the previous week, Ardelyx had 21 more articles in the media than Anthem. MarketBeat recorded 22 mentions for Ardelyx and 1 mentions for Anthem. Ardelyx's average media sentiment score of 0.06 beat Anthem's score of 0.00 indicating that Ardelyx is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ardelyx	1 Very Positive mention(s)	1 Positive mention(s)	17 Neutral mention(s)	1 Negative mention(s)	2 Very Negative mention(s)	Neutral

Anthem has higher earnings, but lower revenue than Ardelyx. Ardelyx is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Ardelyx	$407.32M	2.07	-$61.60M	-$0.22	N/A

Summary

Ardelyx beats Anthem on 11 of the 16 factors compared between the two stocks.

How does Anthem compare to Gyre Therapeutics?

Anthem (NASDAQ:ANTX) and Gyre Therapeutics (NASDAQ:GYRE) are both small-cap healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, risk, profitability, dividends, analyst recommendations, earnings, institutional ownership and valuation.

Anthem currently has a consensus price target of $9.00, suggesting a potential upside of 60.43%. Gyre Therapeutics has a consensus price target of $16.00, suggesting a potential upside of 117.69%. Given Gyre Therapeutics' higher probable upside, analysts plainly believe Gyre Therapeutics is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Gyre Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

90.5% of Anthem shares are owned by institutional investors. Comparatively, 24.0% of Gyre Therapeutics shares are owned by institutional investors. 22.6% of Anthem shares are owned by company insiders. Comparatively, 9.5% of Gyre Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market. Comparatively, Gyre Therapeutics has a beta of 1.89, meaning that its stock price is 89% more volatile than the broader market.

Gyre Therapeutics has higher revenue and earnings than Anthem. Gyre Therapeutics is trading at a lower price-to-earnings ratio than Anthem, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Gyre Therapeutics	$116.59M	7.03	$5.03M	-$0.21	N/A

Anthem has a net margin of 0.00% compared to Gyre Therapeutics' net margin of -15.47%. Gyre Therapeutics' return on equity of -6.57% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Gyre Therapeutics	-15.47%	-6.57%	-5.35%

In the previous week, Gyre Therapeutics had 2 more articles in the media than Anthem. MarketBeat recorded 3 mentions for Gyre Therapeutics and 1 mentions for Anthem. Gyre Therapeutics' average media sentiment score of 0.17 beat Anthem's score of 0.00 indicating that Gyre Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Gyre Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Gyre Therapeutics beats Anthem on 9 of the 15 factors compared between the two stocks.

How does Anthem compare to Achieve Life Sciences?

Achieve Life Sciences (NASDAQ:ACHV) and Anthem (NASDAQ:ANTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, earnings, valuation, risk, institutional ownership, dividends, analyst recommendations and media sentiment.

Achieve Life Sciences has a beta of 2.3, meaning that its stock price is 130% more volatile than the broader market. Comparatively, Anthem has a beta of -0.98, meaning that its stock price is 198% less volatile than the broader market.

33.5% of Achieve Life Sciences shares are held by institutional investors. Comparatively, 90.5% of Anthem shares are held by institutional investors. 1.8% of Achieve Life Sciences shares are held by insiders. Comparatively, 22.6% of Anthem shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Anthem's return on equity of -53.52% beat Achieve Life Sciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Achieve Life Sciences	N/A	-511.12%	-82.35%
Anthem	N/A	-53.52%	-48.63%

Achieve Life Sciences presently has a consensus target price of $15.50, suggesting a potential upside of 121.11%. Anthem has a consensus target price of $9.00, suggesting a potential upside of 60.43%. Given Achieve Life Sciences' stronger consensus rating and higher possible upside, equities analysts clearly believe Achieve Life Sciences is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Achieve Life Sciences	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.00
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

In the previous week, Achieve Life Sciences had 8 more articles in the media than Anthem. MarketBeat recorded 9 mentions for Achieve Life Sciences and 1 mentions for Anthem. Achieve Life Sciences' average media sentiment score of 0.43 beat Anthem's score of 0.00 indicating that Achieve Life Sciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Achieve Life Sciences	2 Very Positive mention(s)	2 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Anthem is trading at a lower price-to-earnings ratio than Achieve Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Achieve Life Sciences	N/A	N/A	-$54.65M	-$1.55	N/A
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A

Summary

Achieve Life Sciences beats Anthem on 8 of the 14 factors compared between the two stocks.

How does Anthem compare to Inventiva?

Anthem (NASDAQ:ANTX) and Inventiva (NASDAQ:IVA) are both small-cap healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, risk, institutional ownership, valuation, dividends, earnings, profitability and media sentiment.

Anthem has higher earnings, but lower revenue than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Anthem	N/A	N/A	-$35.17M	-$1.07	N/A
Inventiva	$5.07M	142.57	-$400.67M	N/A	N/A

Anthem has a beta of -0.98, indicating that its share price is 198% less volatile than the broader market. Comparatively, Inventiva has a beta of 0.79, indicating that its share price is 21% less volatile than the broader market.

Anthem presently has a consensus target price of $9.00, indicating a potential upside of 60.43%. Inventiva has a consensus target price of $15.86, indicating a potential upside of 355.67%. Given Inventiva's stronger consensus rating and higher possible upside, analysts clearly believe Inventiva is more favorable than Anthem.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Anthem	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Inventiva	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	2 Strong Buy rating(s)	3.00

Inventiva's return on equity of 0.00% beat Anthem's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Anthem	N/A	-53.52%	-48.63%
Inventiva	N/A	N/A	N/A

In the previous week, Inventiva had 18 more articles in the media than Anthem. MarketBeat recorded 19 mentions for Inventiva and 1 mentions for Anthem. Inventiva's average media sentiment score of 0.19 beat Anthem's score of 0.00 indicating that Inventiva is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Anthem	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Inventiva	5 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral

90.5% of Anthem shares are held by institutional investors. Comparatively, 19.1% of Inventiva shares are held by institutional investors. 22.6% of Anthem shares are held by insiders. Comparatively, 32.0% of Inventiva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Inventiva beats Anthem on 11 of the 13 factors compared between the two stocks.

Get Anthem News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANTX vs. The Competition

Export

Metric	Anthem	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$199.68M	$12.15B	$7.12B	$13.48B
Dividend Yield	N/A	2.65%	2.54%	17.38%
P/E Ratio	-4.94	799.70	274.29	26.31
Price / Sales	N/A	839.94	597.80	86.06
Price / Cash	N/A	15.08	27.22	34.70
Price / Book	2.74	10.61	11.10	6.39
Net Income	-$35.17M	$2.84B	$3.50B	$381.19M
7 Day Performance	4.50%	-2.14%	-1.84%	-0.18%
1 Month Performance	-9.69%	-6.71%	-6.54%	-4.41%
1 Year Performance	309.47%	-4.83%	6.12%	1.68%

Anthem Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANTX Anthem	1.6575 of 5 stars	$5.32 -5.2%	$9.00 +69.2%	+328.2%	$199.68M	N/A	N/A	N/A
SGP Spyglass Pharma	2.5261 of 5 stars	$25.29 -4.6%	$44.00 +74.0%	N/A	$845.58M	N/A	N/A	65	Positive News Analyst Downgrade
ARDX Ardelyx	2.8662 of 5 stars	$3.37 -0.4%	$13.90 +313.1%	-35.6%	$838.52M	$407.32M	N/A	489	Trending News
GYRE Gyre Therapeutics	1.5408 of 5 stars	$7.19 +2.7%	$16.00 +122.5%	-0.8%	$803.43M	$116.59M	N/A	618	Analyst Upgrade
ACHV Achieve Life Sciences	3.2648 of 5 stars	$7.32 -2.9%	$15.50 +111.9%	+122.5%	$751.68M	N/A	N/A	28

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ANTX) was last updated on 10/6/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Anthem (ANTX) Competitors

ANTX vs. SGP, ARDX, GYRE, ACHV, and IVA

How does Anthem compare to Spyglass Pharma?

Summary

How does Anthem compare to Ardelyx?

Summary

How does Anthem compare to Gyre Therapeutics?

Summary

How does Anthem compare to Achieve Life Sciences?

Summary

How does Anthem compare to Inventiva?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Anthem (ANTX) Competitors

ANTX vs. SGP, ARDX, GYRE, ACHV, and IVA

How does Anthem compare to Spyglass Pharma?

Which has better earnings & valuation, ANTX or SGP?

Is ANTX or SGP more profitable?

Do analysts recommend ANTX or SGP?

Does the media refer more to ANTX or SGP?

Do insiders and institutionals hold more shares of ANTX or SGP?

Summary

How does Anthem compare to Ardelyx?

Which has more volatility & risk, ANTX or ARDX?

Do analysts prefer ANTX or ARDX?

Is ANTX or ARDX more profitable?

Do institutionals & insiders hold more shares of ANTX or ARDX?

Does the media favor ANTX or ARDX?

Which has higher valuation & earnings, ANTX or ARDX?

Summary

How does Anthem compare to Gyre Therapeutics?

Do analysts prefer ANTX or GYRE?

Do institutionals and insiders hold more shares of ANTX or GYRE?

Which has more risk and volatility, ANTX or GYRE?

Which has preferable earnings and valuation, ANTX or GYRE?

Is ANTX or GYRE more profitable?

Does the media favor ANTX or GYRE?

Summary

How does Anthem compare to Achieve Life Sciences?

Which has more risk and volatility, ACHV or ANTX?

Do insiders and institutionals hold more shares of ACHV or ANTX?

Is ACHV or ANTX more profitable?

Do analysts rate ACHV or ANTX?

Does the media refer more to ACHV or ANTX?

Which has better earnings and valuation, ACHV or ANTX?

Summary

How does Anthem compare to Inventiva?

Which has higher valuation and earnings, ANTX or IVA?

Which has more risk and volatility, ANTX or IVA?

Do analysts prefer ANTX or IVA?

Is ANTX or IVA more profitable?

Does the media favor ANTX or IVA?

Do institutionals and insiders believe in ANTX or IVA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANTX vs. The Competition

Anthem Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools